Literature DB >> 21414852

Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue.

Yijun Li1, Ryan Cleary, Mark Kellogg, Janet S Soul, Gerard T Berry, Frances E Jensen.   

Abstract

We have developed and validated a simple and sensitive stable isotope dilution liquid chromatography/tandem mass spectrometric (LC-MS/MS) method for the quantification of bumetanide in human serum. Samples were prepared with a simple acetonitrile based protein precipitation. The supernatant was then analyzed directly using LC-MS/MS. Chromatographic separation was achieved on a C18 reversed phase column using a methanol and water gradient. The detection was performed in selected reaction monitoring (SRM) mode via a positive electrospray ionization (ESI) interface. The method had a lower limit of quantification (LLOQ) of 1 ng/mL, linearity up to 1250 ng/mL, intra- and inter-day precision less than 10%, and accuracy within ±10%. This method was also demonstrated to be suitable for the analysis of bumetanide in rat serum and brain tissue. Bumetanide concentrations in rat serum and brain were determined for samples collected at several intervals following intraperitoneal (i.p.) injection of bumetanide, and were used to calculate bumetanide permeability through the blood-brain barrier.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414852      PMCID: PMC3727383          DOI: 10.1016/j.jchromb.2011.02.018

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

1.  Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry.

Authors:  V Sanz-Nebot; I Toro; R Bergés; R Ventura; J Segura; J Barbosa
Journal:  J Mass Spectrom       Date:  2001-06       Impact factor: 1.982

2.  Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry.

Authors:  K Deventer; F T Delbeke; K Roels; P Van Eenoo
Journal:  Biomed Chromatogr       Date:  2002-12       Impact factor: 1.902

3.  Screening for diuretics in human urine by gas chromatography-mass spectrometry with derivatisation by direct extractive alkylation.

Authors:  A M Lisi; G J Trout; R Kazlauskas
Journal:  J Chromatogr       Date:  1991-02-15

4.  Quantitative determination of the loop diuretic bumetanide in urine and pharmaceuticals by high-performance liquid chromatography with amperometric detection.

Authors:  M J Legorburu; R M Alonso; R M Jiménez; E Ortiz
Journal:  J Chromatogr Sci       Date:  2001-10       Impact factor: 1.618

5.  Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.

Authors:  Claudia Brandt; Maia Nozadze; Nina Heuchert; Marta Rattka; Wolfgang Löscher
Journal:  J Neurosci       Date:  2010-06-23       Impact factor: 6.167

6.  High-performance liquid chromatographic assay for bumetanide in plasma and urine.

Authors:  D E Smith
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

7.  Detection of diuretics in horse urine by GC/MS.

Authors:  H W Hagedorn; R Schulz
Journal:  J Anal Toxicol       Date:  1992 May-Jun       Impact factor: 3.367

8.  Bumetanide: potent new "loop" diuretic.

Authors:  M J Asbury; P B Gatenby; S O'Sullivan; E Bourke
Journal:  Br Med J       Date:  1972-01-22

9.  Process control and drug analysis with an on-line capillary electrophoresis system.

Authors:  Heli Sirén; Kaija Luomanperä; Teemu Työppönen; Stella Rovio; Pertti Vastamäki; Pekka Savolahti
Journal:  J Biochem Biophys Methods       Date:  2004-09-30

Review 10.  Bumetanide: a new loop diuretic (Bumex, Roche Laboratories).

Authors:  C E Halstenson; G R Matzke
Journal:  Drug Intell Clin Pharm       Date:  1983-11
View more
  18 in total

1.  NKCC1 upregulation disrupts chloride homeostasis in the hypothalamus and increases neuronal activity-sympathetic drive in hypertension.

Authors:  Zeng-You Ye; De-Pei Li; Hee Sun Byun; Li Li; Hui-Lin Pan
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

Review 2.  Ion transporters in brain tumors.

Authors:  Damin Cong; Wen Zhu; John S Kuo; Shaoshan Hu; Dandan Sun
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

3.  Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Authors:  Gabriele Deidda; Martina Parrini; Shovan Naskar; Ignacio F Bozarth; Andrea Contestabile; Laura Cancedda
Journal:  Nat Med       Date:  2015-03-16       Impact factor: 53.440

Review 4.  Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema.

Authors:  Arjun Khanna; Kristopher T Kahle; Brian P Walcott; Volodymyr Gerzanich; J Marc Simard
Journal:  Transl Stroke Res       Date:  2013-11-22       Impact factor: 6.829

5.  Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.

Authors:  Gregory L Holmes; Chengju Tian; Amanda E Hernan; Sean Flynn; Devon Camp; Jeremy Barry
Journal:  Neurobiol Dis       Date:  2015-03-10       Impact factor: 5.996

6.  Osmoregulation requires brain expression of the renal Na-K-2Cl cotransporter NKCC2.

Authors:  Agnieszka Konopacka; Jing Qiu; Song T Yao; Michael P Greenwood; Mingkwan Greenwood; Thomas Lancaster; Wataru Inoue; Andre de Souza Mecawi; Fernanda M V Vechiato; Juliana B M de Lima; Ricardo Coletti; See Ziau Hoe; Andrew Martin; Justina Lee; Marina Joseph; Charles Hindmarch; Julian Paton; Jose Antunes-Rodrigues; Jaideep Bains; David Murphy
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

7.  A randomised controlled trial of bumetanide in the treatment of autism in children.

Authors:  E Lemonnier; C Degrez; M Phelep; R Tyzio; F Josse; M Grandgeorge; N Hadjikhani; Y Ben-Ari
Journal:  Transl Psychiatry       Date:  2012-12-11       Impact factor: 6.222

8.  A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.

Authors:  Janet S Soul; Ann M Bergin; Christian Stopp; Breda Hayes; Avantika Singh; Carmen R Fortuno; Deirdre O'Reilly; Kalpathy Krishnamoorthy; Frances E Jensen; Valerie Rofeberg; Min Dong; Alexander A Vinks; David Wypij; Kevin J Staley
Journal:  Ann Neurol       Date:  2020-12-03       Impact factor: 10.422

9.  Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.

Authors:  Ryan T Cleary; Hongyu Sun; Thanhthao Huynh; Simon M Manning; Yijun Li; Alexander Rotenberg; Delia M Talos; Kristopher T Kahle; Michele Jackson; Sanjay N Rakhade; Gerard T Berry; Gerard Berry; Frances E Jensen
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

Review 10.  Zebrafish models of cerebrovascular disease.

Authors:  Brian P Walcott; Randall T Peterson
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.